183 related articles for article (PubMed ID: 19356014)
1. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
[TBL] [Abstract][Full Text] [Related]
3. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
4. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
[TBL] [Abstract][Full Text] [Related]
5. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
Teft WA; Welch S; Lenehan J; Parfitt J; Choi YH; Winquist E; Kim RB
Br J Cancer; 2015 Mar; 112(5):857-65. PubMed ID: 25611302
[TBL] [Abstract][Full Text] [Related]
6. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.
Kroetz DL
J Clin Oncol; 2006 Sep; 24(26):4225-7. PubMed ID: 16895999
[No Abstract] [Full Text] [Related]
7. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
[TBL] [Abstract][Full Text] [Related]
8. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
[TBL] [Abstract][Full Text] [Related]
9. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
[TBL] [Abstract][Full Text] [Related]
11. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
12. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.
Takane H; Miyata M; Burioka N; Kurai J; Fukuoka Y; Suyama H; Shigeoka Y; Otsubo K; Ieiri I; Shimizu E
Ther Drug Monit; 2007 Oct; 29(5):666-8. PubMed ID: 17898662
[TBL] [Abstract][Full Text] [Related]
13. Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity.
García Gil S; Ramos Díaz R; Nazco Casariego GJ; Llanos Muñoz M; Viña Romero MM; Martín Calero B; Pérez Pérez JA; Gutiérrez Nicolás F
Med Clin (Barc); 2018 Dec; 151(11):425-430. PubMed ID: 29499902
[TBL] [Abstract][Full Text] [Related]
14. [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
Teruya T; Nakachi A; Shimabukuro N; Toritsuka D; Azuma Y; Hanashiro K; Nishiki T; Ota M; Shimabuku M; Shiroma H
Gan To Kagaku Ryoho; 2015 May; 42(5):585-9. PubMed ID: 25981652
[TBL] [Abstract][Full Text] [Related]
15. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
Cai X; Cao W; Ding H; Liu T; Zhou X; Wang M; Zhong M; Zhao Z; Xu Q; Wang L
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1579-89. PubMed ID: 23892411
[TBL] [Abstract][Full Text] [Related]
16. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
Schulz C; Boeck S; Heinemann V; Stemmler HJ
Anticancer Drugs; 2009 Nov; 20(10):867-79. PubMed ID: 19770637
[TBL] [Abstract][Full Text] [Related]
17. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR
Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783
[TBL] [Abstract][Full Text] [Related]
18. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Glimelius B; Garmo H; Berglund A; Fredriksson LA; Berglund M; Kohnke H; Byström P; Sørbye H; Wadelius M
Pharmacogenomics J; 2011 Feb; 11(1):61-71. PubMed ID: 20177420
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
20. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
